In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Leadership

Set Alert for Leadership

David Or Goliath: Where Is Innovation Winning Through?

With both a big pharma and biotech leadership perspective, David Meeker talks to In Vivo about how smaller firms can more easily fly solo in drug development, challenges effecting the innovative drug development sector in 2019 and the partnering environment for cell and gene therapy companies. 

Leadership Regenerative Medicine BioPharmaceutical
Advertisement

Latest From Leadership

Roche: We’ve Abandoned Budgets And It’s Liberated Employees

Bill Anderson says Roche has scrapped budgets and improved productivity and re-energized teams. But is it too good to be true?

BioPharmaceutical Commercial

Corporate Affairs: Biopharma’s First Line Of Defense Against Scrutiny

Amgen’s Judy Gawlik Brown is using her finance and consumer health background to make the big biotech’s message more authentic and accessible – a brisk reset against today’s disconnected world of alternative facts.

C-Suite Speaks Leadership

GSK's Hal Barron On R&D Progress At Two-Year Mark

Chief scientific officer at GSK, Hal Barron, talks about winning hearts and minds of 10,000 R&D employees, and adopting practices from acquired company Tesaro.

C-Suite Speaks Research and Development Strategies

C-Suite Snippets: Targeting Metastasis In Cancer Therapy

In case you missed it: catch up with snippets from interviews published by In Vivo this month.

Leadership Research and Development Strategies

One Cancer Start-Up’s Resolve To Crack The Mystery Of Metastasis

Rgenix, a New York-based start-up co-founded by three prominent physician researchers, is taking aim at what it contends is the future of cancer treatment:  finding drugs that shut off the biological chain reaction called tumor metastasis – the colonization of malignant cells throughout the body that ends up killing the majority of cancer patients.

Leadership Cancer

C-Suite Snippets: A Fresh View From Old Science

In case you missed it: catch up with snippets from interviews published by In Vivo this month.

Commercial Research and Development Strategies
See All
UsernamePublicRestriction

Register

Advertisement